The management

Executive Board

Laurent Levy, PhD
Chief Executive Officer

Laurent Levy is the co-founder of Nanobiotix and has served as Chief Executive Officer since March 2003. He was first appointed as Chairman of the Executive Board on May 27, 2004. Laurent has extensive experience in sciences and techniques related to nanotechnologies. His research at the frontier of biotechnology and nanotechnologies has resulted in the development of several concrete applications including Nanobiotix lead product candidate NBTXR3, which could expand therapeutic options and improve outcomes for patients with cancer.

Laurent's mission goes beyond simply curing major diseases like cancer. He and his team are on a mission to unlock humanity's limitless potential or, as they call it, to "Expand Life". From exploring the use of nanotechnology to increase processing power and reshape the brain, to resolving the issues of rapid therapeutic clearance to revolutionize the paradigm of how intravenously administered treatments are designed and delivered--and much more. Mr. Levy's true goal is to help inspire humanity to push beyond boundaries and discover a better way of life. Defeating cancer with the team at Nanobiotix and NBTXR3 is the first step, but only one of many on a bold journey.

From 2000 to 2003, prior to the founding of Nanobiotix, Laurent served as consultant for Altran Technologies and worked in the development of the application of nanotechnologies with companies such as Sanofi S.A., Guerbet S.A., and Rhodia S.A., as well as for early-stage biotechnology companies. He has served as President of the Supervisory Board of Valbiotis S.A. (Euronext Paris: ALVAL) since March 2017, was Vice Chairman of the Executive Board of the European Technology Platform on Nanomedicine (ETPN) from December 2012 to June 2019 and as a founding member of the Nanomedicine Translation Advisory Board (a division of ETPN) from June 2014 to June 2019.

Laurent has authored more than 35 international scientific publications and communications, has applied for and secured several patents, and regularly speaks on the topic of using nanoparticles to fight cancer and other diseases. He holds a Doctorate in Physical Chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Université Paris VI Pierre et Marie Curie; UPVI-ESPCI) in Paris and from the CEA (Commissariat à l’Énergie Atomique et aux Énergies Alternatives), and a DEA (advanced studies and diplomas) in Physics of Condensed Matter from the UPVI-ESPCI. Laurent completed his studies with a post-doctoral fellowship at the Institute for Lasers, Photonics and Biophotonics at the State University of New York at Buffalo (SUNY Buffalo). Nanobiotix was created as a spinoff based on the findings from his post-doctoral thesis.


Anne-Juliette Hermant
Chief People Officer

Anne-Juliette Hermant brings over 14 years in talent management and development acquired in different entities at AXA. She worked at AXA Partners for 3 years as Global Head of Talent, Development, Culture and Corporate Responsibility. Before AXA Partners, Anne-Juliette served as Chief Learning Officer of the AXA Group and was the Founder and Head of the AXA Research Fund, a €100 million fund created by the AXA Group to support frontier science in all fields related to an understanding of the risks faced by human society.

Anne-Juliette was born in Strasbourg, France and grew up between the French Caribbean islands of Guyane, Martinique and Guadeloupe. She relocated to Paris to pursue her studies and has remained in the city throughout her career.

Anne-Juliette holds a Ph. D in French literature from the Ecole Normale Supérieure and studied Politics at Sciences Po Paris.


Philippe Mauberna,
Chief Financial Officer

Philippe Mauberna has served as our Chief Financial Officer since May 2013 and as an Executive Board member since August 2013. He has also served as Owner and Director of Impulse Consulting Ltd. since September 2012.

Prior to that, he served as General Manager of MitryChem from 2011 to 2012, as Principal, Life Sciences at Capgemini Consulting from 2010 to 2011 and in senior financial and operation roles at Astellas Pharma from 2002 to 2008. An expert in management and development of financial and operational projects for the pharmaceutical industry, Philippe has been involved in several international projects (UK, Saudi Arabia, South Africa and Indonesia). He has also been heavily involved in financial projects for start-up launches and innovative small and medium-size enterprise development. As a consultant, he has provided strategic change management support for European pharmaceutical companies during their development phases.
Philippe received his master’s degree in finance, management, administration and economy from University PARIS 2 ASSAS and his specialized master's in finance, marketing and law from ISG (Institut Supérieur de Gestion), extended by management training from INSEAD, both in Paris.

Extended Executive Management


Alain Dostie
Chief Operating Officer

Alain Dostie is the Chief Operating Officer (COO) of Nanobiotix. Mr. Dostie served as the Oncology General Manager at Novartis Pharma GmbH in Germany, where he managed a team of several hundred of people and was responsible for more than $1 billion in sales. Previously, he reported within the Novartis group as Oncology General Manager Canada and Oncology Business Unit Head in the Czech Republic and Slovakia.

He also worked as Executive Marketing Director and National Sales Director positions in oncology at Novartis Pharmaceuticals Canada, Inc., Government Affairs Manager at Merck Frosst Canada, Inc. and various positions within Bayer Canada Inc previously in this career.

Mr. Dostie earned his Bachelor of Science in human kinetics from the University of Guelph, in Ontario, Canada.


Patrick Tricoli, Pharm.D., MBA,
CEO of Nanobiotix Corp. & Global Head of Business Development (Nanobiotix)

Patrick Tricoli is CEO of Nanobiotix Corp., the Nanobiotix US affiliate in Cambridge (MA) and Global Head of Business Development of Nanobiotix, focused on building the Nanobiotix US presence while cultivating cross-industry relationships. Prior to Nanobiotix, Patrick was well known for his lead roles at Sanofi in Partnering and Innovation R&D, and subsequently Head of External Innovation Europe, spanning 15 years, Europe, Asia, and the US markets where he led multiple teams in developing strong international BD relationships, Corporate Development strategies, and collaborative R&D partnership.

Patrick also currently serves as a Foreign Trade Advisr New England for the French government since 2017. He holds a Pharm D, Master in Pharmacology and Pharmacokinetic and Executive MBA from ESCP Europe.

Brandon Owens
VP, Strategic Marketing and Corporate Communication

Brandon Owens is VP, Strategic Marketing and Corporate Communications at Nanobiotix. Hailing from the Washington, D.C. area, Brandon Owens is a career marketer and prior to Nanobiotix, was at Publicis New York on the Citigroup account. Brandon was responsible for Citi’s global reputation management communications and focused on integrated campaigns meant to influence policy decisions relevant to banking in over 100 different countries.
After studying business at the University of Maryland, Brandon began his career selling software for a small company in Baltimore, Maryland. He then moved to Chicago, Illinois to begin his career in advertising. Brandon moved to New York in 2013 and has since represented brands including Verizon, Diageo, and Citi.
Brandon will lean on his experience in the advertising industry to help deepen public understanding of Nanobiotix’s mission and how that mission leads to the company’s innovations.


Paul Beyou
VP, Strategic Partnership, Qualified Person

Paul Beyou is the VP Strategic Partnership and Qualified Person of Nanobiotix. He has a PhD in pharmacy from the university of Bourgogne and a master’s in general management from ESSEC Business School. Paul Beyou was responsible of pharmaceutical activities in Air liquid for 8 years.
Then, he was member of the executive board of Movianto where he supervised the compliance of pharmaceutical operations. Before coming to Nanobiotix, he worked at SGS,Life Science Laboratory Services, for more than 6 years, firstly responsible for the French market for pharmaceutic laboratory and then Managing Director.
scott website

Scott Wieland, PhD., MBA,
EVP, Development

Scott Wieland is the Executive Vice President, Development at Nanobiotix and brings to the company more than 25 years of experience in Drug Development with a demonstrated history of working in the biotechnology industry.

Skilled in Oncology and CNS, Integrated Development Strategy, Clinical Development, Pre-Clinical, Clinical Operations, Regulatory Affairs and Strategy, Scott is absolutely passionate about drug development.

Prior to joining Nanobiotix he has held several leadership positions in the biopharmaceutical services industry including, Vice President, Global Drug Development, at PRA Health Sciences from August 2017 to April 2020. Previously, he served CytRx corporation as Senior Vice president, Drug Development for over 12 years. He also worked as Vice President, Clinical & Regulatory Affairs at BrainCells, Inc., and VP, Drug Development & Regulatory Affairs at Accera after creating his own consulting company, SW Pharma Management.

As a member of the Nanobiotix leadership team, Scott is responsible for all of the company’s global development strategies and plans and the overall leadership of a number of Nanobiotix service lines & business units – these include Clinical Ops, Project Management, Biometry, Safety, Regulatory and Pre-Clinical Research.

He has strong business development professional skills and holds a PhD from the University of Arizona. He also holds an MBA focused on Management from Webster University.

VVV website

Ventzislav Vassilev, MD.
VP, Global Head Safety Vigilance

Ventzislav Vassilev is the Vice President, Global Head of Safety at Nanobiotix and brings over 20 years of experience within the pharmaceutical industry. He joined Nanobiotix in September 2019, after creating and developing the Medical Safety Department of Galapagos N.V.

His career started at Servier HQ at diverse positions within the Clinical Operations cover the Eastern European countries. In 2006, he was pointed out as Regional Head of Clinical Development in Singapore, when he was in charge of the set up and development of all R&D activities of Servier in South, South-East and Pacific Asia. After 4 years as Head of Medical Affairs and Pharmacovigilance (EMEA) within the CRO industry, Ventzislav Joined Astellas as Global Head of CNS portfolio in their Pharmacovigilance Division in Leiden, Netherlands.

Ventzislav is graduated as Medical Doctor from the Medical University in Sofia, Bulgaria, completed with Postgraduate training in Toxicity of the drugs and Pharmacovigilance from University Paris 7 “Denis Diderot”, Hospital Lariboisière Saint-Louis, Paris, France.

peggy website

Margaret Galluzzi
VP, Global Head Clinical Operations

Peggy’s career has spanned several positions in the healthcare field, from hospital practice to large pharmaceutical to biotech industries.

As a Master’s Prepared Nurse, she had roles in hemodialysis, infection control and management of critical care units. Peggy took the opportunity to change her career when she and her family relocated. She joined the pharmaceutical industry with Roche, based in Lingolsheim, France, continued with Roche in US and moved to Sanofi prior to holding positions at 3 US biotech companies. In these companies, she held leadership positions in Clinical Development Operations, helping to bring new drugs through the regulatory approval process, while building and developing the department and its staff.

Her career has been fueled by her desire to help people, whether it be patients, their families or professional colleagues and staff.

catherine celestin V2

Catherine Celestin
VP, Global Medical Affairs

Catherine Celestin, is the VP, Global Medical Affairs at Nanobiotix. Cathy Brings over 25 years of medical affairs experience at leading global pharmaceutical companies and experience in biotechnology to her new role at Nanobiotix.

She joins Nanobiotix from AstraZeneca where she served as National Liaison lead and External Alliances for the past 5 years. Her extensive experience creating, developing and leading medical affairs groups in the US and globally across a full range of therapeutic areas was demonstrated during her tenure at companies such as Pfizer, Genzyme, and BMS. Cathy has expertise in launching 11 Oncology in a portfolio including targeted therapies and immuno-oncology products.

As a member of the Nanobiotix leadership team, Cathy is responsible for the company’s strategy for medical affairs including HEOR, RWE, evidence generation and scientific communications.

Dr. Celestin earned her BS Pharmacy at St. John’s University, Her Doctorate in Pharmacy at University of Florida, a Global MBA at Duke University, Fuqua School of Business, and a Fellowship in Drug Development at University of North Carolina with the Wellcome Foundation.

Supervisory Board

Laurent Condomine,
Chairman of supervisory board

Laurent Condomine has served as Chairman of our supervisory board since June 2011. After working as a consultant for ADL, Mr. Condomine joined ICI-Pharma (France) in 1973, where he held several positions, including Chief Financial Officer and Commercial Director, before being promoted to Chairman and Chief Executive in 1984. In 1992 he became Vice-President of Business Development of ICI PLC, at the company’s head office in London. In 1993 he was involved in ICI’s de-merger, creating Zeneca PLC, where he held a similar position. In 1998 he played a key role in the merger with Astra, creating AstraZeneca PLC, where he held the position of VP of Business Development, until 2008. He has a master’s degree in Economics, is an HEC graduate and has an MBA from INSEAD.

Enno Spillner,
Supervisory board member

Enno Spillner has served as a supervisory board member and chairman of the audit committee since 2014. He has more than 20 years of experience in the life science industry and currently serves as Chief Financial Officer and Member of the Management Board at German biotech company Evotec SE. From March 2013 until June 2016, he served as Chairman of the Management Board, Chief Executive Officer and Chief Financial Officer of 4SC AG. From September 2005 to March 2013 he acted as Chief Financial Officer of 4SC AG. Mr. Spillner started his life science industry career as Head of Finance and Managing Partner of the Munich-based biotech venture fund, BioM AG. He was also Managing Director of two portfolio companies, ACTIPAC Biosystems GmbH and Munich innovative Biomaterials GmbH. Prior to moving into the life science field, he was engaged in the media and marketing industry. Mr. Spillner earned his Dipl.-Kaufmann degree (master’s degree in business) at the University of Bamberg, Germany. Since December of 2019 he has also joined the Life Science Advisory Board of FCF Fox Corporate Finance.

Anne-Marie Graffin,
Supervisory board member

Anne-Marie Graffin has served as a supervisory board member since 2013, as chairman of the appointments and compensation committee since 2017 and as Deputy Chairman of the supervisory board since July 2017. She has over 20 years of experience in life sciences and pharmaceutical companies. She has served as a non-executive board member of Valneva SE (Nantes, FR – Vienna, AT) since 2013 and of Sartorius Stedim Biotech SA (Aubagne, FR – Goëttingen, Ger) since 2015. After a varied career of over 20 years in the pharmaceutical industry, Ms. Graffin has expertise in both developing market access strategies and driving biotechnology companies’ growth. She has been a consultant to the pharmaceutical industry since 2011, developing many initiatives within the innovation and startups fields, connecting biotech and medtech startups with major EU venture capital firms and investors. Previously, she was a vice president at Sanofi Pasteur MSD, a European leader in the vaccine field, and acted as a member of the Executive Committee. Prior to working at Sanofi Pasteur MSD, she worked for five years at ROC as international brand manager. Ms. Graffin graduated from ESSEC Business School Paris.

Alain Herrera,

Dr. Alain Herrera, has served as a supervisory board member since 2013. Dr. Herrera has more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing. Dr. Herrera currently works at Alain Oncologie Consulting, an oncology consultancy company he started. In addition, Dr. Herrera currently serves as Head of Corporate Development, Managing Director of PharmaEngine Europe Sarl. Previously, Dr. Herrera served as head of the Oncology business at Sanofi-Aventis for 10 years. He also served as Vice President for the Global Oncology Business Strategy and Development from 2007-2008 and Head of the Global Oncology Franchise from 1998-2007. While at Sanofi-Aventis, he contributed to the worldwide registration of Oxaliplatin (Eloxatin®) and Rasburicase (Fasturtec®/Elitek®), as well as the Gastric and Head & Neck indications for Docetaxel (Taxotere®). Prior to Sanofi-Aventis, he served as Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rhône Poulenc). Dr. Herrera has also served as a Hematologist Consultant at Antoine Beclere Hospital since 1991.

Christophe Douat,
Supervisory board observer

Christophe Douat serves as a supervisory board observer and is entitled, in this capacity, to attend all meetings of the supervisory board. Mr. Douat previously served as member of the supervisory board from 2011 until 2017 and from 2006 to 2009 when he was the lead investor. He is currently CEO of Medincell (MEDCL, Euronext), a pharmaceutical company that specializes in drug delivery technologies. Mr. Douat worked at the venture capital company Matignon Investissement & Gestion from 2001 to 2009, where he invested in a broad range of companies, and cofounded Matignon Technologies II, one of Europe’s largest funds specialized in medtech. Mr. Douat is also an alumnus of the Boston Consulting Group. He graduated from École des Mines de Paris, an engineering French “Grande Ecole” and holds an MS (US) and an MBA (Canada).